|Dr. Jerel A. Banks Ph.D., M.D.||CEO & Exec. Chairman||631.7k||N/A||1976|
|Ms. Megan Joan Boston||Exec. Director||348.92k||N/A||1972|
|Mr. Bryan Dulhunty||Chief Financial Officer||N/A||N/A||N/A|
|Dr. Michael Graham||Head of Discovery & Founding Scientist||N/A||N/A||N/A|
|Dr. Craig Lewis||Chief Medical Adviser||N/A||N/A||N/A|
|Dr. Claudia Kloth||Sr. VP of Manufacturing||N/A||N/A||N/A|
Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy and chronic hepatitis B virus infection. The company was founded in 1995 and is headquartered in Hayward, California.
Benitec Biopharma Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.